1. Home /
  2. Pharmaceuticals

Pharmaceuticals

NovoCure Looks Due for a Technical Correction

NovoCure Looks Due for a Technical Correction

Let's look at the charts and indicators in addition to following the fundamentals.

GW Pharma Surges on Marijuana-Based Epilepsy Drug Sales, Analyst Upgrades

GW Pharma Surges on Marijuana-Based Epilepsy Drug Sales, Analyst Upgrades

Shares of GW Pharmaceuticals surge following soaring sales of its marijuana-derived epilepsy drug that prompts two analysts to raise their stock-price targets.

Cambrex Soars on Buyout Deal With Private-Equity Firm Permira

Cambrex Soars on Buyout Deal With Private-Equity Firm Permira

Shares of life-sciences company Cambrex surge after the company strikes a deal to be acquired by pharmaceutical-focused private-equity firm Permira funds for $2.4 billion, including debt.

McKesson, Cardinal Health, AmerisourceBergen Propose Opioid Settlement: Report

McKesson, Cardinal Health, AmerisourceBergen Propose Opioid Settlement: Report

Three pharma distributors propose a $10 billion plan to a group of state attorneys general in opioid-abuse settlement.

A Timeline of Botox's History

A Timeline of Botox's History

A timeline of how Botox became one of the most popular medical beauty procedures.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

Amgen Changes the Narrative With Cancer Drug Breakthrough

Amgen Changes the Narrative With Cancer Drug Breakthrough

Amgen built on the momentum at a recent conference on its Q2 earnings call as management highlighted recent positive developments for its KRAS inhibitor drug.

Simulations Plus Can't Go Up Forever, so It's Time to Book the Profits

Simulations Plus Can't Go Up Forever, so It's Time to Book the Profits

Parabolic moves can be alluring, but if you are long on SLP, consider how far it can fall from here.

3 Watch Items for the Market That Don't Involve the Fed or Brexit

3 Watch Items for the Market That Don't Involve the Fed or Brexit

The trio to keep an eye on are U.S.-China trade talks, business investment and political rhetoric.

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Celgene Posts Strong Second-Quarter Earnings, Raises Guidance

Drugmaker Celgene reports second-quarter adjusted earnings and revenue that beat analysts' forecasts and raises its guidance through the remainder of the year amid strong sales of its cancer and other disease-fighting treatments.